Skip to content

Study · Not a test of the peptide alone · 2026

6 results

A sustained NAD+ supplementation-biosynthesis nanoplatform for metabolic restoration in aged bone regeneration.

Xie F, He Z, Xu S, Bai X, Wang X, Zhang F, Yuan Y, Liu C, Niu D

Bioactive materials25 May 2026

PMID42232748 (opens in a new tab)PMCIDPMC13223721 (opens in a new tab)DOI10.1016/j.bioactmat.2026.05.016 (opens in a new tab)PepBankPUB-42232748
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking NAD+ (nicotinamide adenine dinucleotide).

  1. 01AnimalNot a test of NAD+ (nicotinamide adenine dinucleotide) aloneAnimal study (in vivo)Mechanism

    In aged bone defects, the NAD+ combination platform reduced the proportion of senescent BMSCs.

    In plain wordsIn an aged bone defect model, the NAD+ combination platform reduced the proportion of senescent bone marrow stromal cells.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    DecreaseSenescent BMSC proportion
    Study

    n: not reported in source

    aged bone defects
    Outcome group
    Aging markers · Musculoskeletal

    Measurements

    senescent BMSC proportion
    21.2%
    day 7

    Source sentences

    Summary
    In aged bone defects, N/S@M@P reduced the proportion of senescent BMSCs to 21.2% at day 7 and increased the bone volume fraction (BV/TV) by 119% at 4 weeks.

    In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NAD+ (nicotinamide adenine dinucleotide).

  2. 02AnimalNot a test of NAD+ (nicotinamide adenine dinucleotide) aloneAnimal study (in vivo)Efficacy outcome

    In aged bone defects, the NAD+ combination platform increased bone volume fraction.

    In plain wordsIn an aged bone defect model, the NAD+ combination platform increased bone volume fraction.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    IncreaseBone volume fraction
    Study

    n: not reported in source

    aged bone defects
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    BV/TV increase
    119%
    4 weeks

    Source sentences

    Summary
    In aged bone defects, N/S@M@P reduced the proportion of senescent BMSCs to 21.2% at day 7 and increased the bone volume fraction (BV/TV) by 119% at 4 weeks.

    In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NAD+ (nicotinamide adenine dinucleotide).

  3. 03LabNot a test of NAD+ (nicotinamide adenine dinucleotide) aloneIn vitro (cells)Mechanism

    In senescent BMSCs, the NAD+ supplementation-biosynthesis platform enhanced cellular uptake efficiency.

    In plain wordsIn cells, the NAD+ combination platform increased cellular uptake efficiency.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    IncreaseCellular uptake
    Study

    n: not reported in source

    senescent bone marrow-derived mesenchymal stromal cells
    Outcome group
    Mitochondrial function · Musculoskeletal

    Measurements

    uptake increase
    41%
    N/S@M

    Source sentences

    Summary
    Meanwhile, N/S@M enhanced cellular uptake efficiency by 41.0% through regulating the endocytic pathways of senescent BMSCs.
    1 context sentence
    Summary · context
    This platform employs dual-mesoporous silica nanoparticles to highly load NAD+ and controllably load NAD+ biosynthesis activator, establishing a "supplementation-biosynthesis" strategy for rapid NAD+ replenishment and sustained NAD+ metabolic restoration i…

    In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NAD+ (nicotinamide adenine dinucleotide).

  4. 04LabNot a test of NAD+ (nicotinamide adenine dinucleotide) aloneIn vitro (cells)Mechanism

    In senescent BMSCs, the NAD+ supplementation-biosynthesis strategy increased the NAD+/NADH ratio.

    In plain wordsIn cells, the NAD+ combination strategy increased the NAD+/NADH ratio.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    IncreaseNAD+/NADH ratio
    Study

    n: not reported in source

    senescent bone marrow-derived mesenchymal stromal cells
    Outcome group
    Mitochondrial function · Musculoskeletal

    Measurements

    ratio increase
    11.2 fold
    senescent BMSCs

    Source sentences

    Summary
    This strategy increased the NAD+/NADH ratio by 11.2-fold and increased ATP production by 3.25-fold in senescent BMSCs.

    In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NAD+ (nicotinamide adenine dinucleotide).

  5. 05LabNot a test of NAD+ (nicotinamide adenine dinucleotide) aloneIn vitro (cells)Mechanism

    In senescent BMSCs, the NAD+ supplementation-biosynthesis strategy increased ATP production.

    In plain wordsIn cells, the NAD+ combination strategy increased ATP production.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    IncreaseATP production
    Study

    n: not reported in source

    senescent bone marrow-derived mesenchymal stromal cells
    Outcome group
    Mitochondrial function · Musculoskeletal

    Measurements

    ATP increase
    3.25 fold
    senescent BMSCs

    Source sentences

    Summary
    This strategy increased the NAD+/NADH ratio by 11.2-fold and increased ATP production by 3.25-fold in senescent BMSCs.

    In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NAD+ (nicotinamide adenine dinucleotide).

  6. 06LabNot a test of NAD+ (nicotinamide adenine dinucleotide) aloneIn vitro (cell-free)Other

    In a hydrogel scaffold, the NAD+ supplementation-biosynthesis platform enabled sustained particle release.

    In plain wordsIn lab tests, the NAD+ combination platform released particles over an extended period.

    Peptide
    NAD+ (nicotinamide adenine dinucleotide)
    Outcome
    Not applicableSustained particle release
    Study

    n: not reported in source

    injectable hydrogel scaffold
    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    release duration
    14 days
    hydrogel

    Source sentences

    Summary
    After incorporation into an injectable hydrogel scaffold, N/S@M@P enabled sustained particle release over 14 days, supporting prolonged metabolic restoration.

    In this study, NAD+ (nicotinamide adenine dinucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NAD+ (nicotinamide adenine dinucleotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.